Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 932

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 932
---
TABLE OF CONTENTS

Tvardi Therapeutics, Inc. CONDENSED Statements of Operations
(Amounts in thousands, except share and per share amounts)
(Unaudited)

| ​                                                                         
 ​                                                                         
 Operating expenses:                                                       | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | For the Nine Months EndedSeptember 30, 
 2024                                   
 ​                                      | ​ |          ​ | ​ | ​ 
 ​ | ​ 
 ​ | 2023 
 ​    | ​ |          ​ | ​ | ​ 
 ​ 
 ​ |
|:--------------------------------------------------------------------------|:--|:--|:---------------------------------------|:--|-----------:|:--|:--|:--|:-----|:--|-----------:|:--|:--|
| Research and development                                                  | ​ | ​ | ​                                      | $ |     15,047 | ​ | ​ | ​ | ​    | $ |     11,884 | ​ | ​ |
| General and administrative                                                | ​ | ​ | ​                                      | ​ |      2,258 | ​ | ​ | ​ | ​    | ​ |      2,117 | ​ | ​ |
| Total operating expenses                                                  | ​ | ​ | ​                                      | ​ |     17,305 | ​ | ​ | ​ | ​    | ​ |     14,001 | ​ | ​ |
| Loss from operations                                                      | ​ | ​ | ​                                      | ​ |    -17,305 | ​ | ​ | ​ | ​    | ​ |    -14,001 | ​ | ​ |
| Interest income                                                           | ​ | ​ | ​                                      | ​ |        615 | ​ | ​ | ​ | ​    | ​ |      1,005 | ​ | ​ |
| Net loss                                                                  | ​ | ​ | ​                                      | $ |    -16,690 | ​ | ​ | ​ | ​    | $ |    -12,996 | ​ | ​ |
| Net loss per share attributable to common stockholders, basic and diluted | ​ | ​ | ​                                      | $ |      -0.87 | ​ | ​ | ​ | ​    | $ |      -0.68 | ​ | ​ |
| Weighted-average common shares outstanding, basic and diluted             | ​ | ​ | ​                                      | ​ | 19,192,595 | ​ | ​ | ​ | ​    | ​ | 19,134,072 | ​ | ​ |

The accompanying